Lv3
370 积分 2022-09-13 加入
Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?
21小时前
待确认
Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting
21小时前
已关闭
Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials
21小时前
已关闭
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomised clinical trials of belimumab
21小时前
待确认
Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study
22小时前
已完结
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways
22小时前
已完结
Impact of belimumab on glucocorticoid intake in newly diagnosed systemic lupus erythematosus
22小时前
已完结
Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report
1天前
已完结
Telitacicept use in children with IgA vasculitis nephritis: preliminary observations
1天前
已完结
Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis
1天前
已完结
皖公网安备34019202002308
